Med Spa Valuation Multiples: What Buyers Pay in 2026

Almost every “what’s my med spa worth” article online is written by a broker whose real goal is to get you on a sales call. I run a med spa marketing agency, not a brokerage, so I have no listing to win — which means I can show you the actual multiple math: the real 2026 ranges, the add-back mechanics, and the six levers that decide whether the same clinic sells for 3.2x or 5.5x EBITDA. Run your own numbers in my free med spa valuation calculator as you read.

The 3x–7x EBITDA range — and where deals actually cluster

The honest headline number for 2026: most independent med spas trade between 3x and 7x adjusted EBITDA, and the majority of clean, single-site deals cluster in the 4.0x to 5.5x band. That midpoint is consistent across the sources that publish real ranges. FOCUS Investment Banking’s 2026 medspa multiples dashboard puts standalone med spas at 4x–7x EBITDA and single-site clinics at 3x–6x, with regional chains at 5x–8x and scaled multi-state brands reaching 7x–12x.

Size is the first sorting mechanism. Broker-published 2026 data (CT Acquisitions’ med spa M&A multiples report and Breakwater M&A) breaks down roughly like this:

Notice what that table is really saying: the multiple is not a reward for being a med spa. It is a price on transferable, growing profit. A $400K-profit clinic where the owner injects half the Botox is a job with goodwill attached, and buyers price it that way. A $2M-EBITDA group with four injectors and a general manager is an investable asset, and buyers compete for it.

EBITDA vs SDE vs revenue multiples — which applies at your size

Three different multiples get thrown around, and using the wrong one for your size produces fantasy numbers in both directions.

• SDE (seller’s discretionary earnings) applies to owner-operated clinics, typically under roughly $700K–$1M in profit. It adds the owner’s salary and perks back into earnings because the buyer is usually an individual who will step into the owner’s job. Peak Business Valuation publishes med spa SDE multiples of 2.72x to 3.25x as the typical transacted range for main-street deals.
• Adjusted EBITDA applies once the business runs on a management team and provider staff, generally from about $750K in earnings upward. Here you subtract a market-rate salary for whoever replaces you. This is the language PE groups and MSOs speak, and it is where the 4x–7x+ multiples live.
• Revenue multiples are a sanity check, not a valuation method. Peak’s data shows med spas transacting at roughly 0.53x to 0.98x revenue. Two clinics with identical revenue can have wildly different profit, so nobody serious prices a deal on revenue alone.

The trap I see owners fall into: reading a headline that says “med spas sell for 6x” (an EBITDA figure for a $2M-profit group) and applying it to their $300K-SDE solo practice. That mismatch is exactly why so many listings sit unsold at aspirational prices.

Add-backs explained, with a worked example

Buyers do not pay a multiple of your tax return. They pay a multiple of adjusted earnings — your reported profit, normalized for things that will not exist under new ownership. Getting add-backs right routinely moves a valuation by hundreds of thousands of dollars.

Here is a realistic worked example for a single-location spa doing $2.4M in revenue:

Same business, same year — $410K becomes $600K. At a 4.5x multiple, that normalization is worth $855,000 in price. Two warnings, though. First, every add-back must be documented; buyers’ quality-of-earnings teams strike anything you cannot prove, and Ankura’s medspa due-diligence work notes that aggressive or unsupported add-backs are one of the fastest ways deals get re-traded downward. Second, the owner-salary adjustment cuts both ways: if you inject, sell, and manage for a below-market salary, the buyer subtracts the true cost of replacing you, which can shrink adjusted EBITDA rather than grow it.

The 6 premium drivers, with estimated multiple impact

Within the 3x–7x band, six levers explain most of the spread. The impacts below combine FOCUS’s published premiums with broker-reported ranges; where a figure is my synthesis rather than a published stat, I’ve marked it “est.”

1. Recurring membership revenue. FOCUS quantifies this directly: a practice with 30–40% of revenue from memberships adds roughly 0.5x–1.0x versus an identical non-membership peer. Predictable revenue is the single cheapest multiple lever you control — model yours with my membership MRR calculator.
2. Provider depth. Multiple injectors with their own patient books, plus a non-owner medical director, can add 0.5x–1.0x (est.). One rainmaker injector — especially if it’s you — caps the multiple regardless of profit.
3. Owner-dependence. The inverse of the above. If revenue drops when you take a vacation, expect a 0.5x–1.5x discount (est.) plus a longer earnout. Buyers price the risk that patients came for you.
4. Multi-site operations. FOCUS’s dashboard shows regional chains (5x–8x) trading a full turn or two above single sites (3x–6x). A proven second location demonstrates a repeatable playbook, which is what platform buyers are actually purchasing.
5. Growth rate. A clinic growing 20%+ annually with a full booking calendar and a working patient-acquisition engine earns 0.5x–1.0x over a flat one (est.). This is where marketing shows up in enterprise value — documented, diversified lead flow (not just the owner’s Instagram) is an asset a buyer can underwrite. It’s a big part of why I push clients toward durable systems in my med spa marketing work rather than founder-dependent channels.
6. Clean financials and compliance. Accrual books, provider-level production reports, documented Good Faith Exams, and a compliant MSO/ownership structure don’t add a premium so much as they protect one — sloppy books and murky corporate-practice-of-medicine structures are the most common reasons buyers cut price or walk. My 2026 med spa advertising compliance guide covers the marketing side of that same diligence checklist.

Why PE and MSO roll-ups are setting the top of the range

The reason the top of the range keeps stretching is consolidation. AmSpa’s industry data counts more than 11,000 U.S. med spas with average per-location revenue of $1.4M in 2024 (up about 7% year over year), and repeat-patient rates climbing from 65% to 73% between 2022 and 2024 — a fragmented, growing, increasingly recurring-revenue industry, which is precisely the profile private equity hunts.

The 2025–26 deal tape backs that up. MedSpa Partners has acquired 40+ clinics across North America, backed by a $275M continuation fund anchored by Morgan Stanley’s PE arm. Shore Capital’s Empower Aesthetics, Thurston Group’s Alpha Aesthetics (which raised $93M in January 2026), and Leon Capital’s Advanced MedAesthetic Partners are all actively buying add-ons, per AmSpa’s 2025 M&A year-in-review and CT Acquisitions’ 2026 report. With over 90% of med spas still independently owned and several large platforms expected to recapitalize in 2026–27, brokers broadly anticipate another aggressive acquisition wave.

What this means for you: platform buyers paying 10x–14x for scaled assets can afford to pay 5x–7x for quality add-ons and still create value on the spread. That arbitrage is why a well-prepared $1M-EBITDA clinic in a growth market can attract multiple bidders — and why an unprepared one gets a single lowball offer.

Worked case: the same $600K-EBITDA spa at 3.2x vs 5.5x

Take the spa from our add-back example — $600K adjusted EBITDA — and look at two versions of it.

Same profit. A $1.38M difference in price. Nothing in Spa B’s column is exotic — it is 24 months of deliberate work, which is exactly the window to use.

The 24-month value-building checklist

1. Months 1–3: Move to accrual accounting, separate personal expenses, and start a clean add-back file with receipts. Get a baseline valuation using the tiers above.
2. Months 3–9: Launch or rebuild a membership program with a target of 25%+ of revenue on auto-pay. Hire or develop a second injector and start migrating patients off your personal book.
3. Months 9–15: Delegate operations to a manager. Diversify patient acquisition beyond your personal brand — buyers now check whether you show up in AI-driven search, which is why I offer answer engine optimization for clinics whose only channel is referrals. Plug revenue leaks too; my no-show cost calculator shows how much EBITDA a 15% no-show rate quietly burns.
4. Months 15–24: Document SOPs, verify your medical-director and ownership structure with a healthcare attorney, prove one quarter where revenue holds while you take real time off, and interview advisors before you need them. Then read my guide on how to sell your med spa for the process itself.

Want a second set of eyes on this for your clinic? Book a free strategy call or call/text me at +91 97297 12388.

Frequently asked questions

How long does it take to sell a med spa?

Plan on 6–12 months from engaging an advisor to closing: roughly 1–2 months of preparation and marketing materials, 2–4 months of buyer outreach and offers, and 3–6 months of due diligence and legal work. Deals with messy financials or unresolved compliance structures routinely stretch past a year — which is another argument for starting the cleanup 24 months out.

What’s the difference between an asset sale and a stock sale?

In an asset sale, the buyer purchases equipment, patient lists, brand, and goodwill while leaving your legal entity (and most of its liabilities) behind — buyers prefer this, and most smaller med spa deals close this way. In a stock (equity) sale, the buyer acquires the entity itself, which is often better for the seller on taxes and is more common in larger platform deals. The structure can swing your after-tax proceeds by six figures, so model both with a CPA before you accept a headline price.

How do earnouts work in med spa deals?

An earnout defers part of the price, paid only if the business hits agreed targets (usually revenue or EBITDA) over 1–3 years after closing. Buyers use them to bridge valuation gaps and to keep owner-dependent clinics performing through transition. Expect a larger earnout the more the business depends on you personally. Negotiate targets you can actually control, and get the measurement definitions (whose accounting, what add-backs) in writing.

Do PE buyers really pay more than individual buyers?

For clinics that fit their model, yes. Platform-backed buyers paying 10x–14x at the top of the market (per FOCUS’s 2026 dashboard) can pay 5x–7x for add-ons that individual buyers, who rely on SBA financing and their own labor, typically cannot match. But PE only pays up for transferable EBITDA — multiple providers, recurring revenue, management in place. Owner-operated solo practices generally still sell to individuals at SDE multiples.

Does marketing actually affect my valuation multiple?

Indirectly but materially. Buyers underwrite the durability of your patient flow: a clinic acquiring patients through owned, documented channels — search, memberships, email, a booking system that captures every inquiry — supports the growth-rate and owner-independence premiums (est. 0.5x–1.0x each). A clinic whose leads all come from the founder’s personal following gets discounted for exactly the same reason. Even small leaks matter at a multiple: every $10K of EBITDA lost to missed calls costs roughly $45K–$55K of enterprise value at mid-range multiples — my missed-call calculator puts a number on yours.

What multiple should I use for a quick back-of-napkin estimate?

If you’re owner-operated with under $500K in owner earnings, multiply SDE by roughly 2.7x–3.3x (Peak Business Valuation’s published range). If you have a management team and $750K+ in adjusted EBITDA, start at 4x–5x and adjust up or down using the six drivers above. Then pressure-test it in the valuation calculator — and treat any single number as a starting hypothesis, not a price.